COMMUNIQUÉS West-GlobeNewswire

Vision Sensing Acquisition Corp. Responds to NASDAQ Letter and Hopeful of Expedient Resolution
26/01/2024
NEW YORK, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW) (the “ Company ” or “ VSAC ”), a special purpose acquisition company, issues an update regarding the previously [...]
Daré Bioscience Announces Executive Team and Board of Directors Changes
26/01/2024
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial [...]
BrightSpring Celebrates First Day of Trading on Nasdaq
26/01/2024
Will Make $100 Million Equity Grant to 20,000 Employees LOUISVILLE, Ky., Jan. 26, 2024 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) today marked its first day [...]
Autonomix Medical, Inc. Announces Closing of $11.2 Million in Gross Proceeds from Initial Public Offering
26/01/2024
Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical [...]
NADP and ADA Achieve Loss Ratio Compromise at NCOIL
26/01/2024
Model legislation offers middle ground solution on loss ratios DALLAS, Jan. 26, 2024 (GLOBE NEWSWIRE) -- The National Association of Dental Plans (NADP) has successfully negotiated with the American Dental Association ( [...]
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
26/01/2024
PRESS RELEASE AB SCIENCE ANNOUNCES AN UPDATE IN THE MARKETING AUTHORIZATION APPLICATION OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS AT THE EUROPEAN MEDICINES AGENCY A DECISION FROM THE EUROPEAN MEDICINES AGENCY IS [...]
AB Science fait le point sur la demande d’autorisation de mise sur le marché du masitinib dans la sclérose latérale amyotrophique auprès de l’Agence Européenne des Médicaments
26/01/2024
COMMUNIQUE DE PRESSE AB SCIENCE FAIT LE POINT SUR LA DEMANDE D'AUTORISATION DE MISE SUR LE MARCHÉ DU MASITINIB DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE AUPRÈS DE L'AGENCE EUROPÉENNE DES MÉDICAMENTS LA DÉCISION DE L' [...]
Zealand Pharma major shareholder announcement: Van Herk Investments
26/01/2024
Company announcement – No. 6 / 2024 Zealand Pharma major shareholder announcement: Van Herk Investments Copenhagen, Denmark, 26 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a [...]
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
26/01/2024
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
26/01/2024
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation [...]
GRI Bio Announces Reverse Stock Split
26/01/2024
GRI’s common stock is expected to begin trading on a post-split adjusted basis on January 30, 2024 LA JOLLA, CA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a [...]
Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical
26/01/2024
SAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated [...]
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
26/01/2024
UC Davis Medical Center, a top regional and nationally ranked medical center, is the third academic center to participate in the FemBloc pivotal trial since enrollment began last quarter - UC Davis Professor of the [...]
SS Innovations Announces Filing of Pre-Submission Application to the Center for Devices and Radiological Health (CDRH) of the United States Food and Drug Administration
26/01/2024
FORT LAUDERDALE, Fla., Jan. 26, 2024 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (OTC: SSII), a developer of innovative surgical robotic technologies dedicated to making [...]
Inspire Medical Systems, Inc. Announces Jerry C. Griffin, M.D. to Retire from its Board after Sixteen Years of Service
26/01/2024
MINNEAPOLIS, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive [...]
CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024
26/01/2024
Q3W schedule of CRB-701 (SYS6002) demonstrates a 43% ORR and 71% DCR at predicted therapeutically relevant doses All assessable nectin-4 positive study participants with mUC and cervical cancer treated at or above this [...]
Apellis Announces Negative CHMP Opinion for Pegcetacoplan for GA in the European Union and Plans to Seek Re-Examination of Application
26/01/2024
WALTHAM, Mass., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted [...]
Pharvaris to Present at the WSAAI Annual Meeting 2024
26/01/2024
ZUG, Switzerland, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, [...]
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
26/01/2024
January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor Relations Disa Tuominen +45 6038 5826 dkditu@chr-hansen.com Press Relations Sanne Seyer-Hansen +45 6038 6207 dksash@chr- [...]

Pages